Effect of rosiglitazone maleate (Avandia) on carotid intima media thickness, brachial artery reactivity, glucose metabolism, blood lipid concentrations, body fat distribution, and biochemical markers of cardiovascular risk in patients with the HIV metabolic syndrome

Trial Profile

Effect of rosiglitazone maleate (Avandia) on carotid intima media thickness, brachial artery reactivity, glucose metabolism, blood lipid concentrations, body fat distribution, and biochemical markers of cardiovascular risk in patients with the HIV metabolic syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Metabolic syndrome
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Dec 2009 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov
    • 15 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top